Developer docs
API playgroundTry for free, no card

Search company profiles

Frazier Life Sciences

Full company profile

uuid00002l3

Namestring
Frazier Life Sciences
Legal namestring
Frazier Life Sciences Management, L.P.
Company typeenum
Private
Founded yearint
1991
Descriptiontext

Frazier Life Sciences is the dedicated biopharmaceutical venture capital arm of Frazier Healthcare Partners, a private healthcare investment firm founded in 1991. The Life Sciences division invests in private and publicly traded companies that discover, develop, and commercialize innovative therapeutics across immunology, oncology, neuroscience, and rare diseases, frequently taking lead investor positions in Series A and B financings and also participating in post-IPO equity rounds and structured private placements. Its core offering is the Frazier Life Sciences Fund — a $1.3 billion dedicated life sciences investment vehicle closed in October 2025, among the largest life-science VC fundraises of 2025 — and the legal entity through which the division operates is Frazier Life Sciences Management, L.P., a Delaware limited partnership.

Within the broader Frazier Healthcare Partners platform, Frazier Life Sciences sits alongside two sibling strategies — Frazier Healthcare Partners Growth Buyout (US middle-market healthcare buyouts) and Frazier Structured Solutions (bespoke structured financing) — together forming a three-pronged healthcare investment platform. The firm is headquartered in Menlo Park with operating offices in Seattle, WA and New York, NY, and runs a lean team of 11–50 professionals.

Frazier Life Sciences' commercial model is institutional venture capital: it raises dedicated fund vehicles from institutional LPs and deploys capital into biopharmaceutical companies, with recent lead and co-lead positions including AirNexis Therapeutics ($200M Series A), cAMPfield Therapeutics ($180M Series A), Sidewinder Therapeutics ($137M Series B, co-led with Novartis Venture Fund), Achieve Life Sciences (up to $354M private placement), Angitia Biopharmaceuticals ($130M Series D), Maze Therapeutics ($115M Series D and $150M post-IPO follow-on), and others. The firm generates revenue through management fees on committed capital and carried interest on realizations (not publicly disclosed), with fund terms and fee structures not publicly available.

Short descriptiontext

Frazier Life Sciences is the biopharmaceutical venture capital arm of Frazier Healthcare Partners, investing in private and public companies developing innovative therapeutics across immunology, oncology, neuroscience, and rare diseases via a $1.3B life sciences fund.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biopharmaceutical venture capital, life sciences investment, healthcare private equity, therapeutics funding, drug development capital
Industry2 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Venture Capital
Social media profiles1 record
Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Frazier Life Sciences is the dedicated biopharmaceutical venture capital arm of Frazier Healthcare Partners. It raises dedicated life sciences fund vehicles from institutional investors and deploys that capital into private and publicly traded companies developing and commercializing innovative biopharmaceuticals, typically leading or co-leading Series A, Series B, Series D, and post-IPO equity financings.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Frazier Life Sciences is the dedicated biopharmaceutical investment arm of Frazier Healthcare Partners, operating as a single fund strategy rather than a multi-module software product. Its core offering is the Frazier Life Sciences Fund (a $1.3 billion life sciences investment vehicle) which invests in private and publicly traded companies developing innovative biopharmaceuticals. As part of the broader Frazier Healthcare Partners platform, it sits alongside two sibling strategies — Frazier Healthcare Partners Growth Buyout and Frazier Structured Solutions — together forming the firm's three-pronged healthcare investment platform.

Product and service1 record
1Frazier Life Sciences Fund
CategoryInvestment vehicle / venture capital fund
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

A large dedicated life sciences and biotechnology venture capital firm that invests across early- and late-stage therapeutic companies, directly comparable to Frazier Life Sciences in fund scale, sector focus, and lead-investor role.

TypeDirect peer
Description

An early-stage biotech-focused venture capital firm that builds and invests in innovative therapeutics companies; comparable in therapeutic-area focus and lead-investor model, though typically at earlier stages than Frazier.

TypeDirect peer
Description

A healthcare-focused investment firm that invests across public and private biopharma; directly comparable as a peer lead/co-lead in large biotech financings (e.g., co-led Parabilis Medicines' Series F alongside Frazier).

TypeDirect peer
Description

A healthcare-dedicated investment firm with multi-billion-dollar private equity, venture, and public equity funds focused on biopharmaceuticals; directly comparable in AUM scale and therapeutic-stage breadth.

TypeDirect peer
Description

A healthcare-focused venture capital firm investing across biotech, medical devices, and healthcare services; closely comparable as a lead investor in private biopharma financings.

TypeDirect peer
Description

An early-stage venture capital firm focused on building next-generation life sciences companies; comparable in therapeutic focus and stage of investment.

TypeDirect peer
Description

The dedicated life sciences investment platform of Bain Capital, investing across private and public biopharma at scale; comparable in fund size and ability to lead large financings.

TypeBroad incumbent
Description

One of the world's largest venture capital firms with a significant healthcare and life sciences practice; broadly comparable as a healthcare investor, though NEA invests across technology and healthcare rather than specializing only in biopharma.

TypeBroad incumbent
Description

A bioplatform innovation company that creates and funds breakthrough life sciences ventures; comparable in therapeutic innovation focus but typically originates companies internally rather than investing purely externally.

10Baker Bros. Advisors
TypeDirect peer
Description

A long-tenured, healthcare-dedicated investment firm focused on public and private biopharmaceutical companies; directly comparable in life sciences focus and willingness to invest across the cap table.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment60 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frazier Life Sciences

Life Sciences Venture Capitalfrazierhealthcare.com

Frazier Life Sciences is the biopharmaceutical venture capital arm of Frazier Healthcare Partners, investing in private and public companies developing innovative therapeutics across immunology, oncology, neuroscience, and rare diseases via a $1.3B life sciences fund.

What Frazier Life Sciences does

Frazier Life Sciences is the dedicated biopharmaceutical venture capital arm of Frazier Healthcare Partners, a private healthcare investment firm founded in 1991. The Life Sciences division invests in private and publicly traded companies that discover, develop, and commercialize innovative therapeutics across immunology, oncology, neuroscience, and rare diseases, frequently taking lead investor positions in Series A and B financings and also participating in post-IPO equity rounds and structured private placements. Its core offering is the Frazier Life Sciences Fund — a $1.3 billion dedicated life sciences investment vehicle closed in October 2025, among the largest life-science VC fundraises of 2025 — and the legal entity through which the division operates is Frazier Life Sciences Management, L.P., a Delaware limited partnership.

Within the broader Frazier Healthcare Partners platform, Frazier Life Sciences sits alongside two sibling strategies — Frazier Healthcare Partners Growth Buyout (US middle-market healthcare buyouts) and Frazier Structured Solutions (bespoke structured financing) — together forming a three-pronged healthcare investment platform. The firm is headquartered in Menlo Park with operating offices in Seattle, WA and New York, NY, and runs a lean team of 11–50 professionals.

Frazier Life Sciences' commercial model is institutional venture capital: it raises dedicated fund vehicles from institutional LPs and deploys capital into biopharmaceutical companies, with recent lead and co-lead positions including AirNexis Therapeutics ($200M Series A), cAMPfield Therapeutics ($180M Series A), Sidewinder Therapeutics ($137M Series B, co-led with Novartis Venture Fund), Achieve Life Sciences (up to $354M private placement), Angitia Biopharmaceuticals ($130M Series D), Maze Therapeutics ($115M Series D and $150M post-IPO follow-on), and others. The firm generates revenue through management fees on committed capital and carried interest on realizations (not publicly disclosed), with fund terms and fee structures not publicly available.

Frazier Life Sciences firmographics

Firmographics
Name
Frazier Life Sciences
Legal name
Frazier Life Sciences Management, L.P.
Website
https://frazierhealthcare.com
Company type
Private
Founded year
1991
Operating status
Operating
Headcount range
101–250 employees
Short description
Frazier Life Sciences is the biopharmaceutical venture capital arm of Frazier Healthcare Partners, investing in private and public companies developing innovative therapeutics across immunology, oncology, neuroscience, and rare diseases via a $1.3B life sciences fund.
Ownership category
akta.pro rank

Frazier Life Sciences industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Scientific Research and Development Services (5417)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Biopharmaceutical venture capital
  • Life sciences investment
  • Healthcare private equity
  • Therapeutics funding
  • Drug development capital

Where Frazier Life Sciences is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Markets served

Frazier Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Frazier Life Sciences product offering

Product offering

Core offering

Frazier Life Sciences is the dedicated biopharmaceutical venture capital arm of Frazier Healthcare Partners. It raises dedicated life sciences fund vehicles from institutional investors and deploys that capital into private and publicly traded companies developing and commercializing innovative biopharmaceuticals, typically leading or co-leading Series A, Series B, Series D, and post-IPO equity financings.

Product overview

Frazier Life Sciences is the dedicated biopharmaceutical investment arm of Frazier Healthcare Partners, operating as a single fund strategy rather than a multi-module software product. Its core offering is the Frazier Life Sciences Fund (a $1.3 billion life sciences investment vehicle) which invests in private and publicly traded companies developing innovative biopharmaceuticals. As part of the broader Frazier Healthcare Partners platform, it sits alongside two sibling strategies — Frazier Healthcare Partners Growth Buyout and Frazier Structured Solutions — together forming the firm's three-pronged healthcare investment platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Frazier Life Sciences Fund

Companies that use Frazier Life Sciences

Customer profile

Ideal customer profiles1 record

Frazier Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Frazier Life Sciences partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights5 records

Frazier Life Sciences competitors and assessment

Company assessment

Direct peers

  • ARCH Venture Partners: A large dedicated life sciences and biotechnology venture capital firm that invests across early- and late-stage therapeutic companies, directly comparable to Frazier Life Sciences in fund scale, sector focus, and lead-investor role.
  • Atlas Venture: An early-stage biotech-focused venture capital firm that builds and invests in innovative therapeutics companies; comparable in therapeutic-area focus and lead-investor model, though typically at earlier stages than Frazier.
  • RA Capital Management: A healthcare-focused investment firm that invests across public and private biopharma; directly comparable as a peer lead/co-lead in large biotech financings (e.g., co-led Parabilis Medicines' Series F alongside Frazier).
  • OrbiMed Advisors: A healthcare-dedicated investment firm with multi-billion-dollar private equity, venture, and public equity funds focused on biopharmaceuticals; directly comparable in AUM scale and therapeutic-stage breadth.
  • Versant Ventures: A healthcare-focused venture capital firm investing across biotech, medical devices, and healthcare services; closely comparable as a lead investor in private biopharma financings.
  • 5AM Ventures: An early-stage venture capital firm focused on building next-generation life sciences companies; comparable in therapeutic focus and stage of investment.
  • Bain Capital Life Sciences: The dedicated life sciences investment platform of Bain Capital, investing across private and public biopharma at scale; comparable in fund size and ability to lead large financings.
  • Baker Bros. Advisors: A long-tenured, healthcare-dedicated investment firm focused on public and private biopharmaceutical companies; directly comparable in life sciences focus and willingness to invest across the cap table.

Broad incumbents

  • New Enterprise Associates (NEA): One of the world's largest venture capital firms with a significant healthcare and life sciences practice; broadly comparable as a healthcare investor, though NEA invests across technology and healthcare rather than specializing only in biopharma.
  • Flagship Pioneering: A bioplatform innovation company that creates and funds breakthrough life sciences ventures; comparable in therapeutic innovation focus but typically originates companies internally rather than investing purely externally.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Frazier Life Sciences social profiles

Digital presence

Frazier Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Frazier Life Sciences leadership team

Management profile

Number of profiles

Profiles2 records

Frazier Life Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Frazier Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Frazier Life Sciences M&A and investment

M&A and investment

M&A

Investments60 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Frazier Life Sciences

What does Frazier Life Sciences do?

Frazier Life Sciences is the dedicated biopharmaceutical venture capital arm of Frazier Healthcare Partners. It raises dedicated life sciences fund vehicles from institutional investors and deploys that capital into private and publicly traded companies developing and commercializing innovative biopharmaceuticals, typically leading or co-leading Series A, Series B, Series D, and post-IPO equity financings.

Is Frazier Life Sciences a public or private company?

Frazier Life Sciences is a private company. It is classified as private equity controlled and is currently operating.

When was Frazier Life Sciences founded?

Frazier Life Sciences was founded in 1991. It employs 101 to 250 people.

Where is Frazier Life Sciences based?

Frazier Life Sciences is headquartered in Seattle, United States, in the North America region.

Who are Frazier Life Sciences's main competitors?

Direct peers on record are ARCH Venture Partners, Atlas Venture, RA Capital Management, OrbiMed Advisors, Versant Ventures, 5AM Ventures, Bain Capital Life Sciences and Baker Bros. Advisors. Broad incumbents are New Enterprise Associates (NEA) and Flagship Pioneering.

Does Frazier Life Sciences have an API?

No public API is recorded for Frazier Life Sciences.

What industry is Frazier Life Sciences in?

Frazier Life Sciences's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 5417 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechCity goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to NasdaqCity Therapeutics went public with a $200 million IPO, offering 11.1 million shares at $18, above its expected range. The company will use the proceeds for RNAi drug trials, including CITY-FXI and CITY-RBP4. Frazier Life Sciences also listed its second biotech-focused SPAC on Nasdaq.Renaissance CapitalBiotech-focused SPAC Frazier Life Sciences Acquisition II prices $75 million IPOFrazier Life Sciences Acquisition II raised $75 million by offering 7.5 million shares at $10, without warrants or rights. The biotech-focused SPAC, led by Albert Cha, will trade on Nasdaq under FLSC, targeting a company developing new therapies.Renaissance CapitalBiotech SPAC Frazier Life Sciences Acquisition II files for a $75 million IPOFrazier Life Sciences Acquisition II filed with the SEC to raise up to $75 million in an IPO, offering 7.5 million shares at $10. The SPAC, led by Albert Cha, targets biotech and plans to list on Nasdaq under FLSC, with Jefferies as bookrunner.Defense WorldMaze Therapeutics, Inc. $MAZE is Frazier Life Sciences Management L.P.’s 8th Largest PositionFrazier Life Sciences Management L.P. increased its stake in Maze Therapeutics by 10.2% in Q2, holding 5,032,915 shares worth $150.18 million. Insiders sold shares totaling $2.4 million in September, and the stock trades below its 50-day and 200-day moving averages.Defense World3,750,000 Shares in Shattuck Labs, Inc. $STTK Purchased by Frazier Life Sciences Management L.P.Frazier Life Sciences Management L.P. acquired a new position in Shattuck Labs, buying 3.75 million shares worth about $26 million in Q2. Insiders sold 53,875 shares in the last 90 days, and analysts have a consensus Buy rating with a $12.78 price target.Defense WorldFrazier Life Sciences Management L.P. Takes $19 Million Position in Relay Therapeutics, Inc. $RLAYFrazier Life Sciences Management L.P. acquired a new position in Relay Therapeutics, buying 1,015,693 shares valued at approximately $19 million in Q2. The stake represents 0.46% of the company, and 96.98% of the stock is held by institutional investors. Analysts rate the stock a Moderate Buy with an average price target of $25.92.Defense WorldFrazier Life Sciences Management L.P. Buys New Stake in Achieve Life Sciences, Inc. $ACHVFrazier Life Sciences Management L.P. bought a new stake in Achieve Life Sciences, purchasing 7,614,836 shares valued at about $49.7 million in Q2. The stake represents 1.1% of the portfolio, and the company's stock opened at $8.49. Analysts have an average "Buy" rating with a consensus price target of $15.00.Defense WorldFrazier Life Sciences Management L.P. Sells 1,900,000 Shares of BridgeBio Pharma, Inc. $BBIOFrazier Life Sciences Management L.P. sold 1.9 million BridgeBio Pharma shares in Q2, reducing its stake by 55.1% to 1.55 million shares. Analysts have an average "Moderate Buy" rating with a $101.53 target price. The company reported Q2 EPS of -$0.78, missing estimates, but revenue rose 120.4% year-over-year.Defense WorldFrazier Life Sciences Management L.P. Acquires 18,650,000 Shares of Allogene Therapeutics, Inc. $ALLOFrazier Life Sciences Management L.P. increased its stake in Allogene Therapeutics by 491.2% in Q2, buying 18.65 million shares to hold 22.45 million, representing 6.5% of the company. Allogene reported Q2 EPS of -$0.13, beating estimates of -$0.17, with revenue of $4.64 million.Defense WorldAura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P.Frazier Life Sciences Management L.P. increased its stake in Aura Biosciences by 39.2% in Q2, buying 2 million additional shares to hold 7.1 million. The fund's position is 1.1% of its portfolio, and institutional investors own 96.75% of the company.